Home Cart Sign in  
Chemical Structure| 1609402-14-3 Chemical Structure| 1609402-14-3

Structure of HA15
CAS No.: 1609402-14-3

Chemical Structure| 1609402-14-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

HA15 emerges as a potent and specific inhibitor of ER chaperone BiP/GRP78/HSPA5, inhibiting the ATPase activity of BiP and demonstrating anti-cancer properties.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of HA15

CAS No. :1609402-14-3
Formula : C23H22N4O3S2
M.W : 466.58
SMILES Code : CC(NC1=NC(C2=CC=CC(NS(=O)(C3=C4C=CC=C(N(C)C)C4=CC=C3)=O)=C2)=CS1)=O
MDL No. :MFCD30377202
InChI Key :LBSMEKVVMYSTIH-UHFFFAOYSA-N
Pubchem ID :73890923

Safety of HA15

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of HA15

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SCC25 10 μM 24 hours YUM70 treatment reduced c-MYC protein levels and upregulated c-MYC mRNA levels, indicating that YUM70 reduces c-MYC levels through post-transcriptional mechanisms. PMC11294750
SCC15 10 μM 24 hours YUM70 treatment reduced c-MYC protein levels and upregulated c-MYC mRNA levels, indicating that YUM70 reduces c-MYC levels through post-transcriptional mechanisms. PMC11294750
cisR-2 10 μM 24 hours YUM70 treatment reduced c-MYC protein levels and upregulated c-MYC mRNA levels, indicating that YUM70 reduces c-MYC levels through post-transcriptional mechanisms. PMC11294750
cisR-3 10 μM 24 hours YUM70 treatment reduced c-MYC protein levels and upregulated c-MYC mRNA levels, indicating that YUM70 reduces c-MYC levels through post-transcriptional mechanisms. PMC11294750
U87 cells 10 μM 72 hours HA15 combined with TAK-243 significantly inhibited the proliferation of U87 cells PMC8960808
LN229 cells 10 μM 72 hours HA15 combined with TAK-243 significantly inhibited the proliferation of LN229 cells PMC8960808
A427 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
H460 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
HCT116 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
LS180 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
PANC-1 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
CFPAC-1 10 μM 24 hr HA15 treatment significantly decreased KRAS protein level, leading to apoptosis and loss of cell viability. PMC9516447
HT29 cells 31 μM 24 hours HA15 significantly inhibited HT29 cell viability and induced apoptosis PMC7583989
HCT116 cells 16.6 μM 24 hours HA15 significantly inhibited HCT116 cell viability and induced apoptosis PMC7583989

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice MIA PaCa-2 pancreatic cancer xenograft model 30 mg/kg (MDA-MB-231) or 15 mg/kg (SUM149) Daily until tumors reached 10mm in diameter YUM70 treatment significantly reduced c-MYC protein expression in MIA PaCa-2 tumors. PMC11294750
nude mice U87 orthotopic xenograft model intracranial injection 30 mg/kg Once daily for 7 days HA15 combined with TAK-243 significantly inhibited the growth of intracranial GBM and prolonged the survival of tumor-bearing mice PMC8960808

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.72mL

2.14mL

1.07mL

21.43mL

4.29mL

2.14mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories